. 2006 Mar;4 Suppl 1().

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer

Robert W Carlson 1 Elizabeth Brown  Harold J Burstein  William J Gradishar  Clifford A Hudis  Charles Loprinzi  Eleftherios Paul Mamounas  Edith A Perez  Kathleen Pritchard  Peter Ravdin  Abram Recht  George Somlo  Richard L Theriault  Eric P Winer  Antonio C Wolff  National Comprehensive Cancer Network  
  • PMID: 16507275
  •     35 citations


The National Comprehensive Cancer Network (NCCN) first published the NCCN Breast Cancer Treatment Guidelines in 1996. The Guidelines address the treatment of all stages of breast cancer across the spectrum of patient care and have been updated yearly. Adjuvant therapy for breast cancer has undergone an especially rapid evolution over the past few years. Therefore, the NCCN Breast Cancer Guidelines Panel was supplemented by additional experts to form the Adjuvant Therapy Task Force to provide a forum for an extended discussion and expanded input to the adjuvant therapy recommendations for the Breast Cancer Treatment Guidelines. Issues discussed included methods of risk-stratification for recurrence; how biologic markers such as HER2 status, quantitative estrogen receptor, or genetic markers can be incorporated as prognostic or predictive factors; and how age, menopausal status, and estrogen receptor levels impact benefits from chemotherapy and endocrine therapy. Additionally, the task force discussed the strategies for use of aromatase inhibitors in postmenopausal women and the potential incorporation of trastuzumab into adjuvant therapy of women with HER2/neu positive breast cancer. This supplement summarizes the background data and ensuing discussion from the Adjuvant Task Force meeting.

Other Links

Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.
Stefan Paepke, Volker R Jacobs, +5 authors, Marion Kiechle-Bahat.
J Cancer Res Clin Oncol, 2007 Sep 07; 133(12). PMID: 17805570
Letrozole in the neoadjuvant setting: the P024 trial.
Matthew J Ellis, Cynthia Ma.
Breast Cancer Res Treat, 2007 Nov 21; 105 Suppl 1. PMID: 17912634    Free PMC article.
Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS.
Melinda E Sanders, Eduardo C Dias, +7 authors, Richard M Caprioli.
J Proteome Res, 2008 Apr 05; 7(4). PMID: 18386930    Free PMC article.
The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California.
Marilyn L Kwan, Christine B Ambrosone, +16 authors, Lawrence H Kushi.
Cancer Causes Control, 2008 May 15; 19(10). PMID: 18478338    Free PMC article.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts.
Lydia Usha, Bita Tabesh, +5 authors, John S Coon.
J Hematol Oncol, 2008 Aug 16; 1. PMID: 18702822    Free PMC article.
Gene expression profiling of breast cancer.
Ting Bao, Nancy E Davidson.
Adv Surg, 2008 Oct 29; 42. PMID: 18953822    Free PMC article.
Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.
Michael J Hassett, Melissa E Hughes, +7 authors, Jane C Weeks.
J Clin Oncol, 2008 Oct 29; 26(34). PMID: 18955448    Free PMC article.
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
Genet Med, 2009 Jan 07; 11(1). PMID: 19125125    Free PMC article.
Adjuvant hormonal therapy use among insured, low-income women with breast cancer.
Gretchen Kimmick, Roger Anderson, +3 authors, Rajesh Balkrishnan.
J Clin Oncol, 2009 May 20; 27(21). PMID: 19451445    Free PMC article.
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
BIG 1-98 Collaborative Group, Henning Mouridsen, +10 authors, Alan S Coates.
N Engl J Med, 2009 Aug 21; 361(8). PMID: 19692688    Free PMC article.
Highly Cited.
Axillary sentinel lymph node biopsy after mastectomy: a case report.
Diego A Vicente, Leonard R Henry, +2 authors, DeeDee Smart.
World J Surg Oncol, 2010 Jul 14; 8. PMID: 20618969    Free PMC article.
Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response.
Jianbo He, Stephen A Whelan, +6 authors, Helena R Chang.
Int J Proteomics, 2011 Nov 24; 2011. PMID: 22110952    Free PMC article.
Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?
Donna H Odierna, Aimee Afable-Munsuz, +5 authors, Ninez A Ponce.
Per Med, 2011 Dec 23; 8(6). PMID: 22190978    Free PMC article.
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
Catherine M Kelly, Philip S Bernard, +7 authors, Lajos Pusztai.
Oncologist, 2012 Mar 16; 17(4). PMID: 22418568    Free PMC article.
Beliefs and perceptions of women with newly diagnosed breast cancer who refused conventional treatment in favor of alternative therapies.
Dennis L Citrin, Diane L Bloom, +2 authors, Christopher G Lis.
Oncologist, 2012 Apr 26; 17(5). PMID: 22531358    Free PMC article.
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
P Dubsky, M Filipits, +17 authors, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Ann Oncol, 2012 Oct 05; 24(3). PMID: 23035151    Free PMC article.
A survey of breast cancer physicians regarding patient involvement in breast cancer treatment decisions.
Grace Clarke Hillyer, Dawn L Hershman, +6 authors, Alfred I Neugut.
Breast, 2012 Oct 31; 22(4). PMID: 23107518    Free PMC article.
Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Clara Chen, Rahul Dhanda, +2 authors, Debra A Patt.
J Oncol Pract, 2013 Aug 15; 9(4). PMID: 23942918    Free PMC article.
Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.
E A Rakha, D Soria, +6 authors, I O Ellis.
Br J Cancer, 2014 Mar 13; 110(7). PMID: 24619074    Free PMC article.
Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.
Agnieszka K Witkiewicz, Uthra Balaji, Erik S Knudsen.
Clin Cancer Res, 2014 Jul 23; 20(18). PMID: 25047707    Free PMC article.
The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
Terri Patricia McVeigh, Lauren M Hughes, +4 authors, Michael J Kerin.
Eur J Cancer, 2014 Sep 23; 50(16). PMID: 25240289    Free PMC article.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
Hao Cai, Xiangyu Li, +6 authors, Zheng Guo.
Oncotarget, 2015 Nov 04; 6(42). PMID: 26527319    Free PMC article.
The Performance of the Nottingham Prognosis Index and the Adjuvant Online Decision Making Tool for Prognosis in Early-stage Breast Cancer Patients.
Mehri Rejali, Mehdi Tazhibi, +2 authors, Reyhane Mokarian.
Int J Prev Med, 2015 Nov 26; 6. PMID: 26605014    Free PMC article.
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.
Meagan B Myers.
Pharmgenomics Pers Med, 2016 Feb 10; 9. PMID: 26858530    Free PMC article.
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Jan C Brase, Ralf Kronenwett, +2 authors, Marcus Schmidt.
Microarrays (Basel), 2013 Jan 01; 2(3). PMID: 27605191    Free PMC article.
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
Harry D Bear, Wen Wan, +8 authors, Amy P Sing.
J Surg Oncol, 2017 Apr 14; 115(8). PMID: 28407247    Free PMC article.
Cardio-oncology in the older adult.
Prajwal Reddy, Chetan Shenoy, Anne H Blaes.
J Geriatr Oncol, 2017 May 14; 8(4). PMID: 28499724    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.
Charles E Geyer, Gong Tang, +8 authors, Norman Wolmark.
NPJ Breast Cancer, 2018 Nov 21; 4. PMID: 30456299    Free PMC article.
Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.
Monika K Krzyzanowska, Jim A Julian, +6 authors, Eva Grunfeld.
BMC Cancer, 2019 Sep 07; 19(1). PMID: 31488084    Free PMC article.
Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database.
Zeina A Nahleh, Elizabeth B Elimimian, +3 authors, Cassann N Blake.
Breast Cancer (Auckl), 2020 Aug 22; 14. PMID: 32821110    Free PMC article.
Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Vanessa B Sheppard, Jun He, +9 authors, Mahlet G Tadesse.
J Manag Care Spec Pharm, 2019 May 01; 25(5). PMID: 31039059    Free PMC article.
Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria.
Jamal Zekri, Meteb Al-Foheidi, +2 authors, Ayman Rasmy.
Breast Care (Basel), 2021 Jan 16; 15(6). PMID: 33447239    Free PMC article.